Pinova Therapeutics

Pinova Therapeutics was a clinical-stage biotechnology company focused on developing novel small molecule therapies for rare and orphan diseases, with a primary emphasis on Cystic Fibrosis. The company's lead program, PTX-022 (also known as S-777469), was a potent and selective P2X7 receptor antagonist licensed from Shionogi. Pinova aimed to address the inflammatory component of Cystic Fibrosis, providing a complementary approach to existing CFTR modulators by reducing lung inflammation and damage. In 2019, the company was acquired by Vertex Pharmaceuticals to bolster its leadership in the Cystic Fibrosis market and expand its pipeline into inflammatory disease mechanisms. The acquisition integrated Pinova's P2X7 expertise into Vertex's broader research and development efforts.